OBJECTIVE: The aim of the present 36-month prospective split-mouth clinical trial was to investigate the peri-implant soft tissue changes and crestal bone loss (CBL) around delayed loaded platform-switched implants placed at crestal and subcrestal levels. MATERIAL AND METHODS:Twenty-three individuals with bilaterally missing either mandibular first or second molars were included. The test and control sites were defined as follows: (i) test sites: implants placed 2 mm below the alveolar crest (subcrestal); (ii) control sites: implants placed at bone level (crestal). Forty-six implants (23 implants in test sites and 23 in control sites) were placed in the center of the healed alveolar ridge in the posterior mandible. Peri-implant bleeding on probing (BOP), probing depth (PD ≥ 4 mm), and CBL was compared at 6, 18, and 36 months of follow-up. P < 0.05 was considered statistically significant. RESULTS:Sixteen males and seven females with a mean age of 43.5 years (29-50) were included. In the control group (n = 23), the highest mean percentage of sites that showed BOP and PD ≥ 4 mm were at 6 months (7.4% and 1.4%, respectively). In the test group (n = 23), the highest mean percentage of sites that showed BOP and PD ≥ 4 mm were at 6 months (2.4% and 1.2%, respectively). The total amount of CBL around crestal and subcrestal implants after 36 months of loading was 0.45 ± 0.2 and 0.3 ± 0.2 mm, respectively. At all follow-up intervals, all intragroup and intergroup comparisons showed no significant differences in BOP, PD ≥ 4 mm, and CBL around implants placed at crestal and subcrestal levels. CONCLUSION: Up to 36 months of follow-up, soft tissue parameters and crestal bone levels can remain equally stable around dental implants placed at crestal and subcrestal levels. The need for long-term follow-up clinical trials is also emphasized.
RCT Entities:
OBJECTIVE: The aim of the present 36-month prospective split-mouth clinical trial was to investigate the peri-implant soft tissue changes and crestal bone loss (CBL) around delayed loaded platform-switched implants placed at crestal and subcrestal levels. MATERIAL AND METHODS: Twenty-three individuals with bilaterally missing either mandibular first or second molars were included. The test and control sites were defined as follows: (i) test sites: implants placed 2 mm below the alveolar crest (subcrestal); (ii) control sites: implants placed at bone level (crestal). Forty-six implants (23 implants in test sites and 23 in control sites) were placed in the center of the healed alveolar ridge in the posterior mandible. Peri-implant bleeding on probing (BOP), probing depth (PD ≥ 4 mm), and CBL was compared at 6, 18, and 36 months of follow-up. P < 0.05 was considered statistically significant. RESULTS: Sixteen males and seven females with a mean age of 43.5 years (29-50) were included. In the control group (n = 23), the highest mean percentage of sites that showed BOP and PD ≥ 4 mm were at 6 months (7.4% and 1.4%, respectively). In the test group (n = 23), the highest mean percentage of sites that showed BOP and PD ≥ 4 mm were at 6 months (2.4% and 1.2%, respectively). The total amount of CBL around crestal and subcrestal implants after 36 months of loading was 0.45 ± 0.2 and 0.3 ± 0.2 mm, respectively. At all follow-up intervals, all intragroup and intergroup comparisons showed no significant differences in BOP, PD ≥ 4 mm, and CBL around implants placed at crestal and subcrestal levels. CONCLUSION: Up to 36 months of follow-up, soft tissue parameters and crestal bone levels can remain equally stable around dental implants placed at crestal and subcrestal levels. The need for long-term follow-up clinical trials is also emphasized.
Authors: Hilario Pellicer-Chover; Julio Rojo-Sanchís; Miguel Peñarrocha-Diago; José Viña-Almunia; David Peñarrocha-Oltra; Maria Peñarrocha-Diago Journal: J Clin Exp Dent Date: 2020-09-01
Authors: H Pellicer-Chover; M Díaz-Sanchez; D Soto-Peñaloza; M-A Peñarrocha-Diago; L Canullo; D Peñarrocha-Oltra Journal: Med Oral Patol Oral Cir Bucal Date: 2019-09-01
Authors: Javier Gil; Clara Sandino; Miguel Cerrolaza; Román Pérez; Mariano Herrero-Climent; Blanca Rios-Carrasco; Jose Vicente Rios-Santos; Aritza Brizuela Journal: J Clin Med Date: 2022-02-16 Impact factor: 4.241